Publications
Silk SE, et al. "First Phase 1b, single-center, age de-escalation trial of the P. falciparum blood-stage malaria vaccine candidate RH5. 1/Matrix-M™: a delayed boost regimen induces high levels of functional antibodies in 5-17 month old Tanzanian infants." medRxiv. 2024:2024-03.
Williams, Barnabas G., et al. "Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex." bioRxiv (2024): 2024-02.
Mertens, Jonas, et al. "Evaluation of Precision of the Plasmodium knowlesi Growth Inhibition Assay for Plasmodium vivax Duffy-Binding Protein-based Malaria Vaccine Development." bioRxiv: 2024-01.
King, Lloyd DW, et al. "Preclinical Development of a Stabilized RH5 Virus-Like Particle Vaccine that Induces Improved Anti-Malarial Antibodies." bioRxiv (2024): 2024-01.
Barrett, Jordan R., et al. "Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens." Frontiers in Immunology 14: 1193079.
Barrett, Jordan Richard, et al. "Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype." bioRxiv (2023): 2023-10.
Silk, Sarah, et al. "Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults." Med (2023).
Hou, Mimi M., et al. "Vaccination with Plasmodium Vivax Duffy-Binding Protein Inhibits Parasite Growth during Controlled Human Malaria Infection." Science Translational Medicine (2023).
Nielsen, Carolyn, et al. "Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine." JCI insight (2023).
Salkeld, Jo, et al. "Repeat controlled human malaria infection of healthy UK adults with blood-stage Plasmodium falciparum: safety and parasite growth dynamics." Front Immunol (2022).
Ragotte, Robert J., Pulido, David, et al. "Heterotypic interactions drive antibody synergy against a malaria vaccine candidate." Nat comms (2022).
Minassian, Angela M., Themistocleous, Yrene, et al. "Controlled human malaria infection with a clone of Plasmodium vivax with high quality genome assembly." JCI Insight (2021).
Minassian, Angela M., et al. "Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination." Med (2021).
Nielsen, Carolyn M., et al. "Protein/AS01B vaccination elicits stronger, more Th2-skewed antigen-specific human T follicular helper cell responses than heterologous viral vectors." Cell Reports Medicine 2.3 (2021): 100207.
Alanine, Daniel GW, et al. "Human antibodies that slow erythrocyte invasion potentiate malaria-neutralizing antibodies." Cell 178.1 (2019): 216-228.
Rawlinson, Thomas A., et al. "Structural basis for inhibition of Plasmodium vivax invasion by a broadly neutralizing vaccine-induced human antibody." Nature microbiology 4.9 (2019): 1497-1507.
Payne, Ruth O., et al. "Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions." JCI insight 2.21 (2017).
Jin, Jing, et al. "Accelerating the clinical development of protein-based vaccines for malaria by efficient purification using a four amino acid C-terminal ‘C-tag’." International journal for parasitology 47.7 (2017): 435-446.
Payne, Ruth O., et al. "Human vaccination against Plasmodium vivax Duffy-binding protein induces strain-transcending antibodies." JCI insight 2.12 (2017).
Douglas, Alexander D., et al. "A PfRH5-based vaccine is efficacious against heterologous strain blood-stage Plasmodium falciparum infection in aotus monkeys." Cell host & microbe 17.1 (2015): 130-139.
de Cassan, Simone C., et al. "Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax." Frontiers in immunology 6 (2015): 348.
Wright, Katherine E., et al. "Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies." Nature 515.7527 (2014): 427-430.
Sheehy, Susanne H., et al. "Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors." PloS one 7.2 (2012): e31208.
Douglas, Alexander D., et al. "The blood-stage malaria antigen PfRH5 is susceptible to vaccine-inducible cross-strain neutralizing antibody." Nature communications 2.1 (2011): 1-9.
